A study of prevalence and developing mechanisms of insulin-derived amyloidosis in insulin-treated patients with diabetes

A study of prevalence and developing mechanisms of insulin-derived amyloidosis in insulin-treated patients with diabetes - A study of insulin-derived amyloidosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021027

Enrollment

300

Registered

2016-02-15

Start date

2016-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

To screen amyloidosis at the insulin-injection site by a MRI scan. The MRI scan is performed once in a patient.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have been using insulin for six months or more 2) Written informed consent is obtained

Exclusion criteria

Exclusion criteria: 1) Contraindication to MRI

Design outcomes

Primary

Measure	Time frame
Incidence of insulin-derived amyloidosis	—

Secondary

Measure	Time frame
Risk factors for incidence	—

Countries

Japan

Contacts

Public ContactTerumasa Nagase

Tokyo Medical University Ibaraki Medical Center Department of Metabolism and Endocrinology

tnagase@tokyo-med.ac.jp029-887-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026